Systemic lupus erythematosus: all roads lead to type I interferons
Introduction
Patients with systemic lupus erythematosus (SLE) have long been known to display elevated levels of type I interferon (IFN) in their serum. The key role that this cytokine family plays in disease pathogenesis has only emerged, however, in the past few years. We proposed in 2001 that an excess type-I IFN might break peripheral tolerance through the activation of myeloid dendritic cells (DCs). Since then, the roles of type I IFN in two key SLE pathogenic events (i.e. human plasma cell differentiation and activation of CD8 T cells able to generate nucleosomes) have been described. It has also become evident that antigen–antibody complexes containing RNA and DNA activate DCs and B cells through interaction with TLR7/8 and 9, respectively. Thus, lupus-specific autoantigens might act as TLR ligands and contribute to IFN and autoantibody production.
In this article, we will review recent evidence regarding the role of type I IFN in human SLE. We will discuss controversial data on the role of IFN and TLR activation in different murine lupus models. Finally, we will summarize some recent genetic studies that further link the type-I IFN pathway to the pathogenesis of human SLE.
Section snippets
Beyond B and T cells: dendritic cell alterations in SLE
One of the hallmarks of SLE is the loss of tolerance to nuclear antigens and the development of immune complexes that deposit in tissues and cause widespread inflammation. Alteration of T cell–B cell interactions has therefore been proposed as the common pathogenic mechanism that leads to disease [1]. However, the recognition of DCs as efficient stimulators of B and T lymphocytes as well as key controllers of immunity [2] and tolerance [3, 4] has led to the hypothesis that SLE might be driven
IFN-α dysregulation at the center of SLE pathogenesis
Several cytokines have been shown to allow the differentiation of precursor cells into DCs. In particular, IFN-α together with granulocyte-macrophage colony-stimulating factor drive monocytes to become DCs [7, 8, 9]. Accordingly, the DC-inducing property of SLE serum is dependent on IFN-α and correlates with disease activity [5]. Thirteen different IFN-α subtypes together with IFN-β, IFN-ω, IFN-κ and IFN-ɛ/τ (reviewed in [10]) constitute the type I IFN family. A new class of type I IFN-like
IFN-α and immune complexes: the TLR connection and disconnection
The mechanism(s) that leads to unabated production of IFN is currently the subject of debate. There are probably two paths to consider: first, a genetic alteration that prevents the prompt shutdown of IFN production by pDCs; and second, an amplification loop that results from immune complex (IC) activation of pDCs and B cells. We will review the recent studies on the role of ICs and nucleic acids that activate pDCs and B cells by way of Toll-like receptor (TLR)-dependent and -independent
From biology to genomics and back
The genetic basis of human SLE has been the subject of extensive study for more than 20 years. Indeed, genome-wide linkage studies have identified several genetic loci associated to SLE in multiplex families. The multiplicity and complexity of these loci, however, represent a formidable challenge for lupus geneticists. The development in recent years of high-density single nucleotide polymorphism genotyping is allowing both study of previously identified candidate loci and development of
A unified view of SLE pathogenesis
SLE is a remitting disease characterized by flares that progressively result in deterioration of the patient. These flares are often associated with environmental triggers such as viral infections. Infection could trigger the unabated production of IFN-α in SLE patients. We contend that this increased bioavailability of IFN-α is fundamental to SLE pathogenesis. It induces and maintains the generation of mature DCs, tilting the fate of autoreactive T lymphocytes that have escaped central
Conclusions
Alterations of the type I IFN system in SLE were described more than 20 years ago but were forgotten or diluted within the plethora of mouse lupus-like models. The study of SLE patients, however, has recently brought the role of this old cytokine family in the pathogenesis of the disease back into the spotlight. With the help of high throughput technologies, more pieces of the puzzle are being put together. Gene expression profiling, for example, has revealed the almost universal expression of
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Acknowledgements
The authors acknowledge support from the Baylor Health Care System Foundation, the Alliance for Lupus Research (to VP), Defense Advanced Research Planning Agency (to JB), The National Institutes of Health (U19 AIO57234-02, P01 CA084512 and R01 CA078846 to JB and R01 AR46589-01 to VP) and the Research Council of Norway (to LF). JB holds the WW Caruth, Jr Chair in Organ Transplantation Immunology. We thank Carson Harrod for editorial help, Karolina Palucka for critical reading of the manuscript
References (70)
- et al.
Autoimmunity through cytokine-induced dendritic cell activation
Immunity
(2004) - et al.
Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions
Am J Pathol
(2001) - et al.
Presence of cutaneous interferon-alpha producing cells in patients with systemic lupus erythematosus
Lupus
(2001) - et al.
Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6
Immunity
(2003) - et al.
Type I interferons keep activated T cells alive
J Exp Med
(1999) - et al.
Cross-regulation of TNF and IFN-α in autoimmune diseases
Proc Natl Acad Sci USA
(2005) - et al.
FcγRIIa is expressed on natural IFN-α-producing cells (plasmacytoid dendritic cells) and is required for the IFN-α production induced by apoptotic cells combined with lupus IgG
J Immunol
(2003) - et al.
Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9
J Clin Invest
(2005) - et al.
Plasmacytoid dendritic cells control TLR7 sensitivity of naïve B cells via type I IFN
J Immunol
(2005) - et al.
Regulation of B cell tolerance by the lupus susceptibility gene Ly108
Science
(2006)
From T to B and back again: positive feedback in systemic autoimmune disease
Nat Rev Immunol
Dendritic cells and the control of immunity
Nature
Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo
J Exp Med
Tolerogenic dendritic cells
Annu Rev Immunol
Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus
Science
Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells
J Leukoc Biol
Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice
J Exp Med
Type I IFNs enhance the terminal differentiation of dendritic cells
J Immunol
Interferons, interferon-like cytokines, and their receptors
Immunol Rev
IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex
Nat Immunol
IL-28, IL-29 and their class II cytokine receptor IL-28R
Nat Immunol
The nature of the principal type 1 interferon-producing cells in human blood
Science
IRF-7 is the master regulator of type-I interferon-dependent immune responses
Nature
Blood dendritic cells and DC–poietins in systemic lupus erythematosus
Hum Immunol
Experimentally induced recruitment of plasmacytoid (CD123high) dendritic cells in human nasal allergy
J Immunol
Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo
Immunity
Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection
J Exp Med
Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus
Arthritis Rheum
Cutting edge: dissociation between autoimmune response and clinical disease after vaccination with dendritic cells
J Immunol
Mature dendritic cells readily break tolerance in normal mice but do not lead to disease expression
Arthritis Rheum
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
J Exp Med
Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus
Proc Natl Acad Sci USA
Microarray analysis of interferon-regulated genes in SLE
Autoimmunity
Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration
Lupus
Neutralizing interferon alpha as a therapeutic approach to autoimmune diseases
Cytokine Growth Factor Rev
Cited by (254)
Role of cytokines in the pathophysiology of systemic lupus erythematosus
2021, Revista Colombiana de ReumatologiaMicro RNA, circular RNA, neutrophils, and myeloperoxydases in autoimmune diseases
2021, Translational Autoimmunity: Etiology of Autoimmune DiseasesNovel concepts in plasmacytoid dendritic cell (pDC) development and differentiation
2020, Molecular ImmunologyIn systemic lupus erythematosus anti-dsDNA antibodies can promote thrombosis through direct platelet activation
2020, Journal of AutoimmunityCitation Excerpt :Elevated levels of anti-dsDNA antibodies (Abs) in the blood is a characteristic sign of SLE, but the titer of anti-dsDNA Abs can vary during the disease depending on the disease activity [3]. Anti-dsDNA Abs form complexes with DNA that stimulate the peripheral blood mononuclear cells through toll-like receptors 9 followed by production of interferon-α, a strong pro-inflammatory factor [4–6]. Platelets also can be potentially activated by DNA-containing immune complexes through the FcγRIIA receptor [7] or by free anti-DNA Abs through the β3 subunit of the integrins αIIbβ3 and αvβ3 [8].
Overview of the pathogenesis of systemic lupus erythematosus
2020, Systemic Lupus Erythematosus: Basic, Applied and Clinical Aspects